Evidence map›Paper›PMID 39543535›Full record

ArticleBMC cancer2024

Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma.

Angel Chao, Chen-Yang Huang, Willie Yu, Chiao-Yun Lin, Hao Lin, An-Shine Chao, Cheng-Tao Lin, Hung-Hsueh Chou, Kuang-Gen Huang, Huei-Jean Huang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Infiltration of CD8Scientific reports · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Angel Chao *Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Chen-Yang Huang *Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Taoyuan City, 333, Taiwan.
Willie YuCenter for Computational Biology, Duke-NUS Medical School, Singapore, 169857, Singapore.
Chiao-Yun LinDepartment of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Hao LinDepartment of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, 833, Taiwan.
An-Shine ChaoDepartment of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Cheng-Tao LinDepartment of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Hung-Hsueh ChouDepartment of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Kuang-Gen HuangDepartment of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Huei-Jean HuangDepartment of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Ting-Chang ChangDepartment of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan.
Steven G RozenCenter for Computational Biology, Duke-NUS Medical School, Singapore, 169857, Singapore.
Ren-Chin WuGynecologic Cancer Research Center, Linkou Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Taoyuan City, 333, Taiwan. qby@cgmh.org.tw.ORCID http://orcid.org/0000-0003-1439-0874
Chyong-Huey LaiDepartment of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan. laich46@cgmh.org.tw.ORCID http://orcid.org/0000-0002-9977-9645

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian clear cell carcinoma (OCCC) has a disproportionately high incidence among women in East Asia. Patients diagnosed with OCCC tend to experience worse clinical outcomes than those with high-grade serous carcinoma (HGSC) at advanced stages. The unfavorable prognosis of OCCC can be partly attributed to its frequent resistance to conventional chemotherapy. Within a precision medicine framework, we sought to provide a comprehensive molecular characterization of OCCC using whole-exome sequencing to uncover potential molecular targets that may inform novel therapeutic strategies.

methodsWe performed whole-exome sequencing analysis on tumor-normal paired samples from 102 OCCC patients. This comprehensive genomic characterization of a substantial cohort of OCCC specimens was coupled with an analysis of clonal progression.

resultsOn analyzing 102 OCCC samples, ARID1A (67%) and PIK3CA (49%) emerged as the most frequently mutated driver genes. We identified tier 1 or 2 clinically actionable molecular targets in 40% of cases. This included DNA mismatch repair deficiency (n = 1), as well as BRCA2 (n = 1), PIK3CA (n = 36), KRAS

conclusionsOur study provides a comprehensive characterization of the genomic landscape and clonal evolution in OCCC within a substantial cohort. These findings unveil potentially actionable molecular alterations that could be leveraged to develop targeted therapies.

Indexed as

Adenocarcinoma, Clear CellClonal EvolutionExome SequencingMutationOvarian NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsFemaleHumansMiddle AgedMolecular Targeted TherapyPrognosisARID1A protein, humanBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsPIK3CA protein, humanTranscription FactorsClinical actionabilityClonal evolutionMutational signatureOvarian clear cell carcinomaTERT mutationWhole-exome sequencing

Identifiers

PMID39543535
PMCPMC11566382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.